Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.570
-0.040 (-2.48%)
At close: Apr 24, 2025, 4:00 PM
1.570
0.00 (0.00%)
Pre-market: Apr 25, 2025, 7:06 AM EDT
Allogene Therapeutics Revenue
In the year 2024, Allogene Therapeutics had annual revenue of $22.00K, down -76.84%.
Revenue (ttm)
$22.00K
Revenue Growth
-76.84%
P/S Ratio
15,504.80
Revenue / Employee
$96
Employees
229
Market Cap
341.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
ALLO News
- 1 day ago - Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 17 days ago - Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 7 weeks ago - Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - GlobeNewsWire
- 2 months ago - Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities - Seeking Alpha
- 2 months ago - Allogene Therapeutics Announces Participation in March Investor Conference - GlobeNewsWire
- 2 months ago - Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia - GlobeNewsWire